|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hinweise |
|
|
|
Wiss. Komitee |
|
|
|
Adressen |
|
|
|
Presse |
|
|
|
Öffnungszeiten |
|
|
|
Gesellschaften |
|
|
|
Hotelreservierung |
|
|
|
Termine |
|
|
|
Rahmenprogramm |
|
|
|
Gebühren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Online-Anmeldung
Online-Abstracts
Kontakt-Adressen
Congress Center Leipzig
zurück zum Start
Programm-Schwerpunkte-Gesellschaften
|
Symposium 25 Atovaquon/Proguanil (Malarone®): Eine neue Option zur Therapie und Prophylaxe der Malaria |
||
|
15.45 - 17.15 |
Vorsitz U. Bienzle; Berlin, E. Reisinger; Rostock |
|
|
Level 1– Raum 3 |
|
|
|
04.05.2001 |
Sy 25.01 |
Epidemiologie und Resistenzsituation der Malaria |
|
15.45 |
G. Burchard; Berlin |
|
|
Sy 25.02 |
Therapie der Malaria mit Atovaquon/Proguanil |
|
|
16.05 |
J. Knobloch; Tübingen |
|
|
Sy 25.03 |
Malaria-Schnelltests und Stand-by-Therapie: aktueller Stand |
|
|
16.30 |
Th. Löscher; München |
|
|
Sy 25.04 |
Studiendaten zur Prophylaxe mit Atovaquon/Proguanil |
|
|
16.55 |
H.D. Nothdurft; München |
|
|
Dieses Symposium wird gesponsert und ausgerichtet von Glaxo Smith Kline Pharma |
||